---
title: "Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285457203.md"
description: "Cutia Therapeutics has received marketing authorization from China's National Medical Products Administration for its topical anesthesia cream, CU-30101, which showed comparable efficacy and safety to Pliaglis in Phase III trials. This marks Cutia's first approved topical anesthesia product and is expected to enhance its presence in China's dermatology market. However, market uptake remains uncertain, and investors are advised to exercise caution. Cutia, based in the Cayman Islands and listed in Hong Kong, focuses on dermatology treatments and has a market cap of HK$1.68B."
datetime: "2026-05-06T23:55:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285457203.md)
  - [en](https://longbridge.com/en/news/285457203.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285457203.md)
---

# Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cutia Therapeutics ( (HK:2487) ) has provided an update.

Cutia Therapeutics has obtained marketing authorization from China’s National Medical Products Administration for CU-30101, a localized topical lidocaine and tetracaine cream for anesthesia procedures. The product demonstrated comparable efficacy and safety to reference product Pliaglis in a Phase III trial, with no new safety issues observed.

As the group’s first approved topical anesthesia product and third approved drug overall, CU-30101 is expected to broaden Cutia’s sales channels and support commercialization of future pipeline assets. The approval strengthens the company’s commercial footprint in China’s dermatology treatment and care market, although successful market uptake is not guaranteed and investors are urged to remain cautious.

**More about Cutia Therapeutics**

Cutia Therapeutics is a Cayman Islands-incorporated biopharmaceutical group focused on dermatology treatment and care, with its shares listed in Hong Kong. The company develops and commercializes topical therapies, including minocycline foam and finasteride spray, targeting the broader dermatology market in China.

**Average Trading Volume:** 229,340

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$1.68B

For an in-depth examination of 2487 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)

## Related News & Research

- [Cutia Therapeutics AGM resolutions passed in shareholder vote](https://longbridge.com/en/news/290935117.md)
- [15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China](https://longbridge.com/en/news/290470403.md)
- [SSY Group Wins NMPA Approvals for Parkinson’s and Respiratory Drugs](https://longbridge.com/en/news/290402091.md)
- [Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers](https://longbridge.com/en/news/290619996.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)